Skip to main navigation Skip to search Skip to main content

Health-related utility values of patients with primary Sjögren's syndrome and its predictors

  • Dennis Lendrem
  • , Sheryl Mitchell
  • , Peter McMeekin
  • , Simon Bowman
  • , Elizabeth Price
  • , Colin T Pease
  • , Paul Emery
  • , Jacqueline Andrews
  • , Peter Lanyon
  • , John Hunter
  • , Monica Gupta
  • , Michele Bombardieri
  • , Nurhan Sutcliffe
  • , Costantino Pitzalis
  • , John McLaren
  • , Annie Cooper
  • , Marian Regan
  • , Ian Giles
  • , David Isenberg
  • , Saravanan Vadivelu
  • David Coady, Bhaskar Dasgupta, Neil McHugh, Steven Young-Min, Robert Moots, Nagui Gendi, Mohammed Akil, Bridget Griffiths, Wan Fai Ng
  • Newcastle upon Tyne Hospitals NHS Foundation Trust
  • Newcastle University
  • University Hospitals Birmingham NHS Foundation Trust
  • Great Western Hospitals NHS Foundation Trust
  • University of Leeds
  • Nottingham University Hospitals NHS Trust
  • NHS Greater Glasgow and Clyde
  • Barts Health NHS Trust
  • NHS Fife
  • Hampshire Hospitals NHS Foundation Trust
  • University Hospitals of Derby and Burton NHS Foundation Trust
  • University College London Hospitals NHS Foundation Trust
  • Gateshead Health NHS Foundation Trust
  • South Tyneside and Sunderland NHS Foundation Trust
  • Mid and South Essex NHS Foundation Trust
  • Royal United Hospitals Bath NHS Foundation Trust
  • Portsmouth Hospitals University NHS Trust
  • Liverpool University Hospitals NHS Foundation Trust
  • Sheffield Teaching Hospitals NHS Foundation Trust

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives EuroQoL-5 dimension (EQ-5D) is a standardised preference-based tool for measurement of health-related quality of life and EQ-5D utility values can be converted to quality-adjusted life years (QALYs) to aid cost-utility analysis. This study aimed to evaluate the EQ-5D utility values of 639 patients with primary Sjögren's syndrome (PSS) in the UK. Methods Prospective data collected using a standardised pro forma were compared with UK normative data. Relationships between utility values and the clinical and laboratory features of PSS were explored. Results The proportion of patients with PSS reporting any problem in mobility, self-care, usual activities, pain/discomfort and anxiety/depression were 42.2%, 16.7%, 56.6%, 80.6% and 49.4%, respectively, compared with 5.4%, 1.6%, 7.9%, 30.2% and 15.7% for the UK general population. The median EQ-5D utility value was 0.691 (IQR 0.587-0.796, range -0.239 to 1.000) with a bimodal distribution. Bivariate correlation analysis revealed significant correlations between EQ-5D utility values and many clinical features of PSS, but most strongly with pain, depression and fatigue (R values>0.5). After adjusting for age and sex differences, multiple regression analysis identified pain and depression as the two most important predictors of EQ-5D utility values, accounting for 48% of the variability. Anxiety, fatigue and body mass index were other statistically significant predictors, but they accounted for <5% in variability. Conclusions This is the first report on the EQ-5D utility values of patients with PSS. These patients have significantly impaired utility values compared with the UK general population. EQ-5D utility values are significantly related to pain and depression scores in PSS.

Original languageEnglish
Pages (from-to)1362-1368
Number of pages7
JournalAnnals of the Rheumatic Diseases
Volume73
Issue number7
DOIs
Publication statusPublished - Jul 2014
Externally publishedYes

Fingerprint

Dive into the research topics of 'Health-related utility values of patients with primary Sjögren's syndrome and its predictors'. Together they form a unique fingerprint.

Cite this